Articles related to IMMUNOTHERAPY

An updated review of multiple myeloma management highlights revised high-risk definitions, anti-CD38-based quadruplet induction regimens, evolving maintenance strategies, and increasing use of CAR-T and bispecific immunotherapies across the disease continuum.

A multiplexed cytokine and tumor-antigen mRNA immunotherapy produced durable tumor responses in mouse models of pancreatic ductal adenocarcinoma, with approximately half of treated animals remaining disease-free for up to one year, although clinical relevance remains unproven.

Among 90 pediatric patients with relapsed or refractory B-cell precursor ALL, prior blinatumomab was associated with more relapses at atypical extramedullary sites. The retrospective single-center findings require prospective confirmation.

Emerging evidence suggests microbiome composition may be associated with immunotherapy response, toxicity, and outcomes in kidney cancer. Experts caution that inconsistent methodologies and limited reproducibility continue to challenge microbiome biomarker development.

A phase 1 study of mKRAS-VAX in 20 patients at high risk for PDAC showed KRAS-specific T-cell responses in most participants. No high-grade adverse events occurred, but clinical prevention data remain early.

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.